Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 1.00 |
| ▸ | EBP | Q15125 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emopamil SCHEMBL93921 | 1.00 | SIGMAR1 (1.00) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| Levemopamil SCHEMBL8668419 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| Emopamil SCHEMBL30127166 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL7965554 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL10453393 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL7956324 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL7971207 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL9490836 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL7969360 | 0.92 | SIGMAR1 (0.84) | SIGMAR1EBPABCB1CYP3A4ABCC1 | |
| SCHEMBL9493517 | 0.89 | SIGMAR1 (0.79) | SIGMAR1EBPABCB1CYP3A4ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103432091-A | Improved-performance tablet and preparation method thereof | ZHONG SHUGUANG | 2013-12-11 | — | — | CN | claimed |
| CN-101919822-B | Tablet with improved combination properties and preparation method thereof | ZHONG SHUGUANG | 2013-10-23 | — | — | CN | claimed |
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| US-20100311697-A1 | Methods and Compositions for the Treatment of CNS-Related Conditions | ADAMAS PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| US-20100029665-A1 | Methods and Compositions for Treating Migraine Pain | MEYERSON LAURENCE R | 2010-02-04 | — | — | US | claimed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | claimed |
| US-20090253728-A1 | Methods and Compositions for Treating Nociceptive Pain | MEYERSON LAURENCE R | 2009-10-08 | — | — | US | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| EP-0858334-A4 | ANALGESIC IMMEDIATE AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | FAULDING F H & CO LTD (AU) | 2000-08-09 | — | — | EP | claimed |
| EP-0858334-A1 | ANALGESIC IMMEDIATE AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | F.H. FAULDING & CO. LIMITED (AU) | 1998-08-19 | — | — | EP | claimed |
| WO-1997014415-A1 | ANALGESIC IMMEDIATE AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | F.H. FAULDING & CO. LIMITED (AU) | 1997-04-24 | — | — | WO | claimed |
| US-5496818-A | OIL-IN-WATER TYPE; DISPERSED LIPID PHASE OF VEGETABLE OIL, PHOSPHOLIPID EMULSIFIER AND STRONGLY BASIC HYDROPHOBIC PHARMACEUTICAL; AQUEOUS PHASE WITH BUFFER AND SMALL AMOUNT OF IONIZED PHARMACEUTICAL; POSITIVE CHARGE AT EMULSION INTERFACE | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-03-05 | — | — | US | claimed |
| EP-0456106-B1 | Stable emulsion for pharmaceutical administration, process for its preparation and use thereof as pharmaceutical | KNOLL AG (DE) | 1994-12-07 | — | — | EP | claimed |
| EP-0557290-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | The Children's Medical Center Corporation (US) | 1993-09-01 | — | — | EP | claimed |
| EP-0557290-A4 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS. | CHILDRENS MEDICAL CENTER (US) | 1993-07-14 | — | — | EP | claimed |
| EP-0502418-A1 | Use of levemopamil for the manufacture of a medicament for the treatment of alcohol abuse | BASF CORPORATION (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1992003137-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0456106-A2 | Stable emulsion for pharmaceutical administration, process for its preparation and use thereof as pharmaceutical | KNOLL AG (DE) | 1991-11-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | SIGMAR1 118/4885EBP 4275/4885ABCB1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.